“So our Pharma Services business delivers much stronger growth in the second half of the year aligned with kind of how we modeled the year to start it.”

In context

“derlying market conditions. This happens to do with comparable days, things of that sort. So it's nice to have a good quarter behind us. And then we step up in a logical way from there. But Jim, maybe you want to talk a little bit about the phasing? James Meyer: Yes. When you think about the phasing from Q1 to Q2, you have the impact of the headwind from days in Q1 that doesn't exist in Q2, and you also have a significant comparable change in analytical instruments. So that's really the step-up is those two drivers, Q1 to Q2. And then if you think about the first half to the second half, you obviously have the impact of days, the headwind in Q1, the tailwind in Q4 and you have a meaningfully different revenue phasing profile in pharma services that impacts both to this year. in last year. So our Pharma Services business delivers much stronger growth in the second half of the year aligned with kind of how we modeled the year to start it. Michael Ryskin: Okay. And then a follow-up, if I could. I mean, it sounds like you had another good strong quarter in Pharma and Biotech. You called out bioproduction, you called out clinical research continue to do well. Is there anything in particular that kind of offset that? I think you touched on weaker U.S. A&G and in China, maybe a little bit softness in diagnostics. so is there just any moving pieces in terms of what came out worse than expected to offset some of the strength in pharma and biotech? Marc Casper: No. I mean as I think about the end markets and the growth that we delivered even by the various 4 end markets, they pretty much were what we expected to happen during the quarter. So we knew that pharma and biotech would be the strongest growth of that end market. That was”